AI Article Synopsis
- D-glucaric acid is a valuable organic acid with diverse uses in therapy, food, and materials, leading to a high market value.
- The article focuses on how to sustainably produce D-glucaric acid from glucose using various microbial strains and advanced metabolic control strategies.
- It also compares different strains' efficiency in producing D-glucaric acid and discusses the engineering challenges necessary to optimize production in these "cell factories."
Article Abstract
D-glucaric acid is an important organic acid with numerous applications in therapy, food, and materials, contributing significantly to its substantial market value. The biosynthesis of D-glucaric acid (GA) from renewable sources such as glucose has garnered significant attention due to its potential for sustainable and cost-effective production. This review summarizes the current understanding of the cell factories for GA production in different chassis strains, from static to dynamic control strategies for regulating their metabolic networks. We highlight recent advances in the optimization of D-glucaric acid biosynthesis, including metabolic dynamic control, alternative feedstocks, metabolic compartments, and so on. Additionally, we compare the differences between different chassis strains and discuss the challenges that each chassis strain must overcome to achieve highly efficient GA productions. In this review, the processes of engineering a desirable cell factory for highly efficient GA production are just like an epitome of metabolic engineering of strains for chemical biosynthesis, inferring general trends for industrial chassis strain developments.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11274-024-04097-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Geometric Deep learning Prioritization and Validation of Cannabis Phytochemicals as Anti-HCV Non-nucleoside Direct-acting Inhibitors.
Biomed Eng Comput Biol
December 2024
PharmaQsar Bioinformatics Firm, Kampala, Uganda.
Introduction: The rate of acute hepatitis C increased by 7% between 2020 and 2021, after the number of cases doubled between 2014 and 2020. With the current adoption of pan-genotypic HCV therapy, there is a need for improved availability and accessibility of this therapy. However, double and triple DAA-resistant variants have been identified in genotypes 1 and 5 with resistance-associated amino acid substitutions (RAASs) in NS3/4A, NS5A, and NS5B.
View Article and Find Full Text PDFEffect and safety of intravenous iron compared to oral iron for treatment of iron deficiency anaemia in pregnancy.
Cochrane Database Syst Rev
December 2024
Medical Research Council Clinical Trials Unit, Institute for Clinical Trials and Methodology, University College London, London, UK.
Rationale: Intravenous iron is increasingly used to treat iron-deficient anaemia (IDA) in pregnancy. A previous network meta-analysis suggested that intravenous irons have a greater effect on haematological parameters than oral irons; however, the impact on serious pregnancy complications such as postpartum haemorrhage (PPH) or the need for blood transfusion was unclear. Since then, several new randomised controlled trials (RCTs) have been conducted.
View Article and Find Full Text PDFInfusion Reactions With Alternative Therapies During the National Shortage of Iron Dextran.
Eur J Haematol
January 2025
Henry Ford Health, Detroit, Michigan, USA.
Prior to the national shortage of iron dextran in early 2023, it was the most commonly administered intravenous iron infusion at our institution. After the shortage impacted the health system, alternatives such as iron sucrose and sodium ferric gluconate/sucrose were required that utilized lower doses given at more frequent patient visits. Coinciding with their more prevalent use, an increase in iron infusion reactions was observed.
View Article and Find Full Text PDFBackground: Treatment of end stage renal disease (ESRD) is based on preserving renal functions. Since renal anemia is frequently detected, we use parenteral iron treatments in patients with chronic kidney disease (CKD). However, there need to be more precise and sufficient studies on the effect of these treatments on the rate of decrease in the glomerular filtration rate (GFR).
View Article and Find Full Text PDFComparison of the efficacy and adverse effects of oral ferrous succinate tablets and intravenous iron sucrose: a retrospective study.
BMC Pharmacol Toxicol
September 2024
Department of Colorectal and anal surgery, Shanxi provincial people's hospital, Taiyuan City, 030001, Shanxi Province, China.
Objective: To analyse the clinical efficacy and adverse drug reactions (ADRs) of iron preparations.
Methods: A total of 374 patients with iron deficiency anaemia admitted to our hospital between 1 January and 31 December 2020 were included in this study. They were divided into 2 groups based on their medication regimens: Group A (n = 187) took oral ferrous succinate tablets, and Group B (n = 187) received intravenous iron sucrose.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!